lscancerdiag.com Report : Visit Site

Technical data of the lscancerdiag.com

Geo IP provides you such as latitude, longitude and ISP (Internet Service Provider) etc. informations. Our GeoIP service found where is host lscancerdiag.com. Currently, hosted in Finland and its service provider is Zoner Oy .

the related websites

cafonline.org explainthatstuff.com gov.uk blackhouse.uk.com smsw.co.uk popfax.com teachingyourchild.org.uk 

HTTP Header Analysis

HTTP Header information is a part of HTTP protocol that a user's browser sends to called Apache/2 containing the details of what the browser wants and will accept back from the web server.

DNS

HtmlToText

toggle navigation home company team diagmmr research contact submit samples diagmmr® - diagnostics innovation our mission is to save lives through early detection of lynch syndrome with easy and accurate diagnostic method. lynch syndrome one of the main single causes of colorectal and endometrial cancers, lynch syndrome, i.e. inherited mismatch repair (mmr) deficiency , is carried by up to 1/279 of the population * . inherited defect lynch syndrome (ls) is inherited with 50% probability within affected families. each year, there are 3.5 million new cancer cases within ls spectrum. individual risk individuals with inherited mmr deficiency have more than 70% risk of developing colorectal cancer , compared to 2% in the general population on a global scale. innovative solution the diagmmr ® method developed by ltd is a non-invasive test to detect ls carriers, enabling preventive care and helping save lives. company ltd is committed to reducing cancer mortality rates with a low-cost, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. our vision is to see diagmmr ® as a new global testing standard in ls diagnostics. lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. with a significant proportion of the world’s population carrying the lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by ls. our groundbreaking diagmmr ® assay is an easy functional test that can be used for diagnosis of mmr deficiency i.e. lynch syndrome (previously known as hereditary non­polyposis colorectal cancer; hnpcc). our mission is to save lives through an innovation that dramatically simplifies diagnostics of lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally. team professor minna nyström (prev. nyström­-lahti), phd founder and chairman professor nyström is the leading inventor of diagmmr ® with more than 20 years of experience in the field of lynch syndrome research and has had an active role in both the identification of the ls related genes and mutations as well as the bettering of ls recognition through over 50 scientific publications in the field. prof. nyström is an active member of the international society for gastrointestinal hereditary tumours, insight. dr. minttu kansikas, phd r&d director dr. kansikas has worked on lynch syndrome research in prof. nyström ́s lab for over 9 years and is a co-inventor of diagmmr ® . her doctoral thesis, “recognizing lynch syndrome by dna mismatch repair deficiency” focused on pathogenicity assessment and interpretation of ls associated mutations and functional detection of reduced mismatch repair. mariann kasela, msc researcher msc kasela works as a researcher in ltd and specializes in the functional assessment of mmr proteins. she has broad experience in mmr research, cell culture and biotechnology. dr. jaana putula, phd researcher dr. putula has vast experience in cell culture and works to ensure the meticulous handling of patient samples from sampling to testing. in addition to coordinating the sample handling and running the cell culture processes, she assists with other processes of the diagmmr ® testing. niklas lahti cfo mr. lahti is responsible for managing the strategy and financials of the company and leads the commercialization of the diagmmr ® . he has experience from investment banking and other industries before joining ltd. dr. jukka kantelinen, phd laboratory director dr. kantelinen has worked on dna mismatch repair research in prof. nyström ́s lab for over 11 years. his doctoral thesis, “functional characterization of muts homologue mismatch repair proteins and their variants” focused on functional characterization of ls mutations and the key molecular components of the mmr mechanism. dr. laura vähätalo, phd production manager dr. vähätalo is responsible for the laboratory production of the diagmmr ® assay, as well as the interpretation and management of the results. in addition to the production management, she also specializes in the quantitative detection method. she has extensive experience in molecular biology techniques and biomedical research. anni moilanen, msc researcher msc moilanen works as a researcher in the team. her role is central in producing the molecular components used in diagmmr ® . she has broad experience in molecular biology techniques and also contributes to the cell culture processes and other functions of the lab. from sample to diagnosis diagmmr ® is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing lynch syndrome related cancers. while current ls diagnosis relies on tumor studies, the quantitative diagmmr ® method allows carrier diagnosis based on a non-invasive tissue sample before the person has developed a cancer, without the knowledge and details of an inherited mutation. diagnostic benefits the diagmmr ® innovation has several outstanding benefits compared to the current diagnostic tools: diagmmr ® diagnoses lynch syndrome from a non-malignant tissue sample before tumors appear making it predictive instead of reactive. diagmmr ® is a fast single functional test replacing the current large array of tests. diagmmr ® delivers results that are easy to interpret. diagmmr ® costs less than current test panels, saving significantly in healthcare costs on a global scale. international lynch syndrome research inherited mmr deficiency, i.e. lynch syndrome, gives rise to a broad spectrum of tumors, especially colorectal and endometrial cancers, but also ovarian, gastric, urinary, small bowel, brain and bile duct/gallbladder cancers. the history of international lynch syndrome research can be traced back to 1895 and the discovery of a family cancer syndrome . the disease was characterized by henry t. lynch in 1966 and came to be known as hereditary nonpolyposis colorectal cancer (hnpcc), which in honour of dr. lynch’s findings, was later termed lynch syndrome. the molecular genetics era began in 1993 when a germline mmr gene mutation was identified as a cause of ls . currently lynch syndrome research is being actively carried out worldwide, with an approach that focuses on obtaining a deeper understanding of the molecular mechanism behind ls, enabling preventive diagnosis and personalized medical care. resources international society for gastrointestinal hereditary tumors (insight) is an international multidisciplinary, scientific organization with the mission to improve the quality of care of patients and their families with any condition resulting in hereditary gastrointestinal tumors. the inventors, scientific advisors, key collaborators, and ltd employees have actively participated in the activities of insight. finnish hnpcc is a group formed by leading finnish lynch syndrome researchers. the group is actively involved in several projects on the mmr mechanism and ls in collaboration with central university hospitals in finland. international agency for cancer research (iarc) is the specialized cancer agency of the world health organization. the objective of the iarc is to promote international collaboration in cancer research to adopt preventive measures and reduce cancer mortality. academic research root of diagmmr® the diagmmr ® innovation is based on more than 20 years of academic research at the university of helsinki, where the functional mmr assay research and development has resulted in 7 phds and 30 original peer-reviewed publications in the 2000's. diagmmr ® is an advanced application of an in vitro mmr assay used for the functional characterization of mmr gene mutations. publications nyström, m. & kansikas, m. (2017) predictive cancer diagnostics: ltd has developed diagmmr, an innovative method to detect cancer syndrome before cancers form. pan e

URL analysis for lscancerdiag.com

http://www.lscancerdiag.com//#contact
http://www.lscancerdiag.com/#team
http://www.lscancerdiag.com/
http://www.lscancerdiag.com/#diagmmr
http://www.lscancerdiag.com/#home
http://www.lscancerdiag.com/#research
http://www.lscancerdiag.com/#company
edition.pagesuite-professional.co.uk

Whois Information

Whois is a protocol that is access to registering information. You can reach when the website was registered, when it will be expire, what is contact details of the site with the following informations. In a nutshell, it includes these informations;

Domain Name: LSCANCERDIAG.COM
Registry Domain ID: 1810324505_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.joker.com
Registrar URL: http://www.joker.com
Updated Date: 2017-05-31T10:27:27Z
Creation Date: 2013-06-23T12:42:09Z
Registry Expiry Date: 2018-06-23T12:42:09Z
Registrar: CSL Computer Service Langenbach GmbH d/b/a joker.com
Registrar IANA ID: 113
Registrar Abuse Contact Email: [email protected]
Registrar Abuse Contact Phone: +49.21186767447
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Name Server: NS1.VERKKOTAIKURIT.FI
Name Server: NS2.VERKKOTAIKURIT.FI
DNSSEC: unsigned
URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/
>>> Last update of whois database: 2017-10-14T11:52:49Z <<<

For more information on Whois status codes, please visit https://icann.org/epp

NOTICE: The expiration date displayed in this record is the date the
registrar's sponsorship of the domain name registration in the registry is
currently set to expire. This date does not necessarily reflect the expiration
date of the domain name registrant's agreement with the sponsoring
registrar. Users may consult the sponsoring registrar's Whois database to
view the registrar's reported date of expiration for this registration.

TERMS OF USE: You are not authorized to access or query our Whois
database through the use of electronic processes that are high-volume and
automated except as reasonably necessary to register domain names or
modify existing registrations; the Data in VeriSign Global Registry
Services' ("VeriSign") Whois database is provided by VeriSign for
information purposes only, and to assist persons in obtaining information
about or related to a domain name registration record. VeriSign does not
guarantee its accuracy. By submitting a Whois query, you agree to abide
by the following terms of use: You agree that you may use this Data only
for lawful purposes and that under no circumstances will you use this Data
to: (1) allow, enable, or otherwise support the transmission of mass
unsolicited, commercial advertising or solicitations via e-mail, telephone,
or facsimile; or (2) enable high volume, automated, electronic processes
that apply to VeriSign (or its computer systems). The compilation,
repackaging, dissemination or other use of this Data is expressly
prohibited without the prior written consent of VeriSign. You agree not to
use electronic processes that are automated and high-volume to access or
query the Whois database except as reasonably necessary to register
domain names or modify existing registrations. VeriSign reserves the right
to restrict your access to the Whois database in its sole discretion to ensure
operational stability. VeriSign may restrict or terminate your access to the
Whois database for failure to abide by these terms of use. VeriSign
reserves the right to modify these terms at any time.

The Registry database contains ONLY .COM, .NET, .EDU domains and
Registrars.

  REGISTRAR CSL Computer Service Langenbach GmbH d/b/a joker.com

SERVERS

  SERVER com.whois-servers.net

  ARGS domain =lscancerdiag.com

  PORT 43

  TYPE domain

DOMAIN

  NAME lscancerdiag.com

  CHANGED 2017-05-31

  CREATED 2013-06-23

STATUS
clientTransferProhibited https://icann.org/epp#clientTransferProhibited

NSERVER

  NS1.VERKKOTAIKURIT.FI 84.34.166.22

  NS2.VERKKOTAIKURIT.FI 84.34.147.22

  REGISTERED yes

Mistakes

The following list shows you to spelling mistakes possible of the internet users for the website searched .